Insights from the Editorial Board Member

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 December 2025 | Viewed by 2537

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
2. Department of Biomedical Informatics, Emory University, Atlanta, GA 30322, USA
Interests: prostate cancer; breast cancer; bioinformatics; genomics; transcription; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to summarize and highlight the research results, opinions, and literature reviews of the Editorial Board members of Cancers. In this Special Issue, these members will share their views on current hot research topics, highlighting research trends and the latest innovations and novel findings in cancer research. This Special Issue aims to present basic, translational, and clinical studies on all tumor types, and topics of interest include, but are not limited to, the following:

  • Cancer therapeutics;
  • Cancer biomarkers;
  • Precision medicine;
  • Cancer genomics;
  • Cancer immunology;
  • Cancer biology;
  • Clinical trials;
  • Cancer epidemiology and prevention;
  • Tumor microenvironment and metastasis;
  • Cancer informatics.

Dr. Carlos S. Moreno
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapeutics
  • cancer biomarkers
  • precision medicine
  • cancer genomics
  • cancer immunology
  • cancer biology
  • clinical trials
  • cancer epidemiology and prevention
  • tumor microenvironment and metastasis
  • cancer informatics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Other

3 pages, 155 KiB  
Editorial
Beyond Primary HER2 Expression: Trastuzumab Deruxtecan’s Efficacy in Brain Metastasis
by Glori Das, Stephen T. C. Wong and Hong Zhao
Cancers 2024, 16(20), 3525; https://doi.org/10.3390/cancers16203525 - 18 Oct 2024
Viewed by 696
Abstract
This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in [...] Read more.
This commentary focuses on the DESTINY-Breast12 study, published in Nature Medicine on 13 September 2024, which evaluates the efficacy of Trastuzumab deruxtecan (T-DXd) in treating HER2-positive advanced breast cancer, including those with brain metastases. We emphasize the broadened clinical potential of T-DXd in treating brain metastases from tumors originally classified as HER2-null or HER2-low, extending beyond its current use for breast cancer. This expanded application of T-DXd could provide new hope to patients dealing with challenging brain metastases, addressing an urgent need for effective treatment options. Full article
(This article belongs to the Special Issue Insights from the Editorial Board Member)

Other

Jump to: Editorial

10 pages, 3002 KiB  
Commentary
IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition
by Roberto Piva, Nariman Gharari, Maria Labrador and Sylvie Mader
Cancers 2024, 16(19), 3280; https://doi.org/10.3390/cancers16193280 - 26 Sep 2024
Viewed by 696
Abstract
The metabolic reprogramming characteristic of cancer cells, including the Warburg effect, has long been recognized as a hallmark of malignancy. This commentary explores three recent investigations focusing on the role of wild-type IDH2 in cancer and immune cell function. The first publication identifies [...] Read more.
The metabolic reprogramming characteristic of cancer cells, including the Warburg effect, has long been recognized as a hallmark of malignancy. This commentary explores three recent investigations focusing on the role of wild-type IDH2 in cancer and immune cell function. The first publication identifies wild-type IDH2 as a crucial factor in the survival of triple-negative breast cancer (TNBC) cells, with its inhibition leading to disrupted energy metabolism, reduced tumor growth, and enhanced apoptosis. The second analysis examines the role of IDH2 in CD8+ T cells, revealing that its inhibition promotes the differentiation of memory T cells, thereby enhancing the efficacy of cell-based immunotherapies like CAR T cells. A third investigation supports these findings, demonstrating that IDH2 inhibition in CAR T cells reduces exhaustion, enhances memory T cell formation, and improves anti-tumor efficacy. Collectively, these reports highlight wild-type IDH2 as a promising therapeutic target, with potential applications as a two-edged sword in both cancer treatment and immunotherapy. The development of specific wild-type IDH2 inhibitors could offer new avenues for therapy, particularly in tumors reliant on IDH2 activity as well as in enhancing the effectiveness of CAR T cell therapies. Full article
(This article belongs to the Special Issue Insights from the Editorial Board Member)
Show Figures

Figure 1

Back to TopTop